The effect of price controls on pharmaceutical research. ( 2003).cutting prices by 40 to 50 percent in the United States will lead to between 30 and 60 percent fewer R and D projects being undertaken in the early stage of developing a new drug. Relatively modest price changes, such as 5 or 10 percent, are estimated to have relatively little impact on the incentives for product development – perhaps a negative 5 percent.”
Cost Control: Examining drug price controls around the world. (2018) This examines the impact of high drug prices and price controls in 5 different countries
there is a long-running debate in Washington, D.C., and in state capitols across the country, about whether governments should directly intervene to regulate or set prices for drugs. The following conversation simulates this debate and provides the facts you need to know.
Prescription drug prices: Why the US is an outlier (2017). Various factors contribute to high per capita drug spending in the U.S. While drug utilization appears to be similar in the U.S. and the nine other countries considered, the prices at which drugs are sold in the U.S. are substantially higher. These price differences appear to at least partly explain current and historical disparities in spending on pharmaceutical drugs. U.S. consumers face particularly high out-of-pocket costs, both because the U.S. has a large uninsured population and because cost-sharing requirements for those with coverage are more burdensome than in other countries. Most Americans support reducing pharmaceutical costs. International experience demonstrates that policies like universal health coverage, insurance benefit design that restricts out-of-pocket spending, and certain price control strategies, like centralized price negotiations, can be effective.
Curbing unfair drug prices (2017)
A prescription for disaster (2018). Competition and market forces, not price controls, will drive down drug costs and will do so better than any heavy-handed legislation or regulation. In early 2014, reactions to drug prices reached a fever pitch after Gilead announced its $84,000 list price tag for a 12-week course of the hepatitis C drug Sovaldi and reached a crescendo when Turing Pharmaceuticals, led by former hedge fund manager Martin Shkreli, raised the price of its drug Daraprim from $13.50 a tablet to $750 in September 2015
Tragic toll of drug price controls (2018). Everyone wants lower healthcare costs. But it’s counterproductive to blame companies that create life saving therapies.
Think competition, not price (2017)